LPA signaling is regulated through the primary cilium

a novel target in glioblastoma

Yuriy V. Loskutov, Caryn L. Griffin, Kristina M. Marinak, Andrey Bobko, Naira V. Margaryan, Werner J. Geldenhuys, Jann N Sarkaria, Elena N. Pugacheva

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The primary cilium is a ubiquitous organelle presented on most human cells. It is a crucial signaling hub for multiple pathways including growth factor and G-protein coupled receptors. Loss of primary cilia, observed in various cancers, has been shown to affect cell proliferation. Primary cilia formation is drastically decreased in glioblastoma (GBM), however, the role of cilia in normal astrocyte or glioblastoma proliferation has not been explored. Here, we report that loss of primary cilia in human astrocytes stimulates growth rate in a lysophosphatidic acid (LPA)-dependent manner. We show that lysophosphatidic acid receptor 1 (LPAR1) is accumulated in primary cilia. LPAR1 signaling through Gα12/Gαq was previously reported to be responsible for cancer cell proliferation. We found that in ciliated cells, Gα12 and Gαq are excluded from the cilium, creating a barrier against unlimited proliferation, one of the hallmarks of cancer. Upon loss of primary cilia, LPAR1 redistributes to the plasma membrane with a concomitant increase in LPAR1 association with Gα12 and Gαq. Inhibition of LPA signaling with the small molecule compound Ki16425 in deciliated highly proliferative astrocytes or glioblastoma patient-derived cells/xenografts drastically suppresses their growth both in vitro and in vivo. Moreover, Ki16425 brain delivery via PEG-PLGA nanoparticles inhibited tumor progression in an intracranial glioblastoma PDX model. Overall, our findings establish a novel mechanism by which primary cilium restricts proliferation and indicate that loss of primary cilia is sufficient to increase mitogenic signaling, and is important for the maintenance of a highly proliferative phenotype. Clinical application of LPA inhibitors may prove beneficial to restrict glioblastoma growth and ensure local control of disease.

Original languageEnglish (US)
Pages (from-to)1-15
Number of pages15
JournalOncogene
DOIs
StateAccepted/In press - Jan 11 2018

Fingerprint

Cilia
Glioblastoma
Lysophosphatidic Acid Receptors
Astrocytes
Neoplasms
Growth
Cell Proliferation
lysophosphatidic acid
G-Protein-Coupled Receptors
Heterografts
Organelles
Nanoparticles
Intercellular Signaling Peptides and Proteins
Maintenance
Cell Membrane
Phenotype

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Loskutov, Y. V., Griffin, C. L., Marinak, K. M., Bobko, A., Margaryan, N. V., Geldenhuys, W. J., ... Pugacheva, E. N. (Accepted/In press). LPA signaling is regulated through the primary cilium: a novel target in glioblastoma. Oncogene, 1-15. https://doi.org/10.1038/s41388-017-0049-3

LPA signaling is regulated through the primary cilium : a novel target in glioblastoma. / Loskutov, Yuriy V.; Griffin, Caryn L.; Marinak, Kristina M.; Bobko, Andrey; Margaryan, Naira V.; Geldenhuys, Werner J.; Sarkaria, Jann N; Pugacheva, Elena N.

In: Oncogene, 11.01.2018, p. 1-15.

Research output: Contribution to journalArticle

Loskutov, YV, Griffin, CL, Marinak, KM, Bobko, A, Margaryan, NV, Geldenhuys, WJ, Sarkaria, JN & Pugacheva, EN 2018, 'LPA signaling is regulated through the primary cilium: a novel target in glioblastoma', Oncogene, pp. 1-15. https://doi.org/10.1038/s41388-017-0049-3
Loskutov YV, Griffin CL, Marinak KM, Bobko A, Margaryan NV, Geldenhuys WJ et al. LPA signaling is regulated through the primary cilium: a novel target in glioblastoma. Oncogene. 2018 Jan 11;1-15. https://doi.org/10.1038/s41388-017-0049-3
Loskutov, Yuriy V. ; Griffin, Caryn L. ; Marinak, Kristina M. ; Bobko, Andrey ; Margaryan, Naira V. ; Geldenhuys, Werner J. ; Sarkaria, Jann N ; Pugacheva, Elena N. / LPA signaling is regulated through the primary cilium : a novel target in glioblastoma. In: Oncogene. 2018 ; pp. 1-15.
@article{4490c3a61e3b41d08dcb4096fba6cb0c,
title = "LPA signaling is regulated through the primary cilium: a novel target in glioblastoma",
abstract = "The primary cilium is a ubiquitous organelle presented on most human cells. It is a crucial signaling hub for multiple pathways including growth factor and G-protein coupled receptors. Loss of primary cilia, observed in various cancers, has been shown to affect cell proliferation. Primary cilia formation is drastically decreased in glioblastoma (GBM), however, the role of cilia in normal astrocyte or glioblastoma proliferation has not been explored. Here, we report that loss of primary cilia in human astrocytes stimulates growth rate in a lysophosphatidic acid (LPA)-dependent manner. We show that lysophosphatidic acid receptor 1 (LPAR1) is accumulated in primary cilia. LPAR1 signaling through Gα12/Gαq was previously reported to be responsible for cancer cell proliferation. We found that in ciliated cells, Gα12 and Gαq are excluded from the cilium, creating a barrier against unlimited proliferation, one of the hallmarks of cancer. Upon loss of primary cilia, LPAR1 redistributes to the plasma membrane with a concomitant increase in LPAR1 association with Gα12 and Gαq. Inhibition of LPA signaling with the small molecule compound Ki16425 in deciliated highly proliferative astrocytes or glioblastoma patient-derived cells/xenografts drastically suppresses their growth both in vitro and in vivo. Moreover, Ki16425 brain delivery via PEG-PLGA nanoparticles inhibited tumor progression in an intracranial glioblastoma PDX model. Overall, our findings establish a novel mechanism by which primary cilium restricts proliferation and indicate that loss of primary cilia is sufficient to increase mitogenic signaling, and is important for the maintenance of a highly proliferative phenotype. Clinical application of LPA inhibitors may prove beneficial to restrict glioblastoma growth and ensure local control of disease.",
author = "Loskutov, {Yuriy V.} and Griffin, {Caryn L.} and Marinak, {Kristina M.} and Andrey Bobko and Margaryan, {Naira V.} and Geldenhuys, {Werner J.} and Sarkaria, {Jann N} and Pugacheva, {Elena N.}",
year = "2018",
month = "1",
day = "11",
doi = "10.1038/s41388-017-0049-3",
language = "English (US)",
pages = "1--15",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - LPA signaling is regulated through the primary cilium

T2 - a novel target in glioblastoma

AU - Loskutov, Yuriy V.

AU - Griffin, Caryn L.

AU - Marinak, Kristina M.

AU - Bobko, Andrey

AU - Margaryan, Naira V.

AU - Geldenhuys, Werner J.

AU - Sarkaria, Jann N

AU - Pugacheva, Elena N.

PY - 2018/1/11

Y1 - 2018/1/11

N2 - The primary cilium is a ubiquitous organelle presented on most human cells. It is a crucial signaling hub for multiple pathways including growth factor and G-protein coupled receptors. Loss of primary cilia, observed in various cancers, has been shown to affect cell proliferation. Primary cilia formation is drastically decreased in glioblastoma (GBM), however, the role of cilia in normal astrocyte or glioblastoma proliferation has not been explored. Here, we report that loss of primary cilia in human astrocytes stimulates growth rate in a lysophosphatidic acid (LPA)-dependent manner. We show that lysophosphatidic acid receptor 1 (LPAR1) is accumulated in primary cilia. LPAR1 signaling through Gα12/Gαq was previously reported to be responsible for cancer cell proliferation. We found that in ciliated cells, Gα12 and Gαq are excluded from the cilium, creating a barrier against unlimited proliferation, one of the hallmarks of cancer. Upon loss of primary cilia, LPAR1 redistributes to the plasma membrane with a concomitant increase in LPAR1 association with Gα12 and Gαq. Inhibition of LPA signaling with the small molecule compound Ki16425 in deciliated highly proliferative astrocytes or glioblastoma patient-derived cells/xenografts drastically suppresses their growth both in vitro and in vivo. Moreover, Ki16425 brain delivery via PEG-PLGA nanoparticles inhibited tumor progression in an intracranial glioblastoma PDX model. Overall, our findings establish a novel mechanism by which primary cilium restricts proliferation and indicate that loss of primary cilia is sufficient to increase mitogenic signaling, and is important for the maintenance of a highly proliferative phenotype. Clinical application of LPA inhibitors may prove beneficial to restrict glioblastoma growth and ensure local control of disease.

AB - The primary cilium is a ubiquitous organelle presented on most human cells. It is a crucial signaling hub for multiple pathways including growth factor and G-protein coupled receptors. Loss of primary cilia, observed in various cancers, has been shown to affect cell proliferation. Primary cilia formation is drastically decreased in glioblastoma (GBM), however, the role of cilia in normal astrocyte or glioblastoma proliferation has not been explored. Here, we report that loss of primary cilia in human astrocytes stimulates growth rate in a lysophosphatidic acid (LPA)-dependent manner. We show that lysophosphatidic acid receptor 1 (LPAR1) is accumulated in primary cilia. LPAR1 signaling through Gα12/Gαq was previously reported to be responsible for cancer cell proliferation. We found that in ciliated cells, Gα12 and Gαq are excluded from the cilium, creating a barrier against unlimited proliferation, one of the hallmarks of cancer. Upon loss of primary cilia, LPAR1 redistributes to the plasma membrane with a concomitant increase in LPAR1 association with Gα12 and Gαq. Inhibition of LPA signaling with the small molecule compound Ki16425 in deciliated highly proliferative astrocytes or glioblastoma patient-derived cells/xenografts drastically suppresses their growth both in vitro and in vivo. Moreover, Ki16425 brain delivery via PEG-PLGA nanoparticles inhibited tumor progression in an intracranial glioblastoma PDX model. Overall, our findings establish a novel mechanism by which primary cilium restricts proliferation and indicate that loss of primary cilia is sufficient to increase mitogenic signaling, and is important for the maintenance of a highly proliferative phenotype. Clinical application of LPA inhibitors may prove beneficial to restrict glioblastoma growth and ensure local control of disease.

UR - http://www.scopus.com/inward/record.url?scp=85040344775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040344775&partnerID=8YFLogxK

U2 - 10.1038/s41388-017-0049-3

DO - 10.1038/s41388-017-0049-3

M3 - Article

SP - 1

EP - 15

JO - Oncogene

JF - Oncogene

SN - 0950-9232

ER -